Corticosteroids lead to short-term improvement in cerebral amyloid angiopathy-related inflammation.

Abstract

BACKGROUND:

Cerebral amyloid angiopathy - related inflammation (CAA-ri) is an uncommon manifestation of CAA.

METHODS:

Single-center, retrospective review of all charts with ICD-code I68.0 (CAA) from 2/2/2016-1/1/2020.

RESULTS:

Of 152 CAA cases, 13 (8.6%) were consistent with CAA-ri. Corticosteroid-treatment led to short-term reduction in modified Rankin Scale scores (2.6 ± 1.4 vs. 1.6 ± 1.5; p = 0.01) and T2/FLAIR lesion volume (78.1 ± 52.2 cm3 vs. 30 ± 30.9 cm3, p < 0.01) as well as short-term improvement in post-treatment Clinical Global Impression - Global Change scores compared to pre-treatment scores (clinical: 6 ± 1 vs. 2.6 ± 1.3, p = 0.03; radiological: 4.6 ± 1.9 vs. 1.2 ± 0.4, p = 0.03).

INTERPRETATION:

Corticosteroid-treatment leads to clinical and radiological short-term improvement (class IV evidence).

• Authors: Torge Rempe, Carlos Eduardo Vervloet Sollero, Elsa Rodriguez, Vyas Tenkasi Viswanathan, Aaron Carlson, John Rees, Ibrahim Sacit Tuna, Jesse Kresak, Tirisham Victoria Gyang
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 348 Pg. 577377 (11 15 2020) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 32919147 (Publication Type: Journal Article)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Chemical References

• Adrenal Cortex Hormones
• Prednisolone
• Methylprednisolone

Topics

• Adrenal Cortex Hormones (therapeutic use)
• Aged
• Brain (drug effects, pathology)
• Cerebral Amyloid Angiopathy (complications)
• Female
• Humans
• Inflammation (drug therapy, etiology, pathology)
• Magnetic Resonance Imaging
• Male
• Methylprednisolone (therapeutic use)
• Middle Aged
• Prednisolone (therapeutic use)
• Retrospective Studies